What will be the future after R-CHOP in patient with DLBCL?
B. Coiffier
Pierre-Benie, France
R-CHOP (combination of rituximab plus standard CHOP regimen) has become the standard for treating patients with diffuse large B-cell lymphoma (DLBCL). This combination of 8 cycles of chemo-immunotherapy every 3 weeks was demonstrated as superior to CHOP alone in several studies in different settings. It allows increasing the CR rate, decreasing the relapse rate, prolonging event-free survival, progression-free survival, disease-free survival, and overall survival. This is true in young and elderly patients, in patients with low- or high-risk lymphoma. However, several questions remain for improving on these results.